Current stock page

Stock Analysis

Beta Bionics, Inc. (BBNX) Stock Analysis

Beta Bionics, Inc. (BBNX) stock analysis covering valuation, fundamentals, technical indicators, risk, AIQ Momentum, analyst catalysts, dividends, and the current AIQ Score.

BBNX Stock Analysis Summary

Beta Bionics, Inc. (BBNX) currently has an AIQ Score of 54/100, indicating a neutral setup. Momentum is the strongest factor at 72/100. Risk is the weakest current factor at 36/100. Technical, fundamental, catalyst, dividend, and risk evidence should be read together at the latest market-close snapshot.

Updated Nov 18, 2026 · Market-close data

BBNX at a Glance

Crawlable current metrics from the latest market-close stock snapshot.

MetricCurrent
Price$14.33
AIQ Score54/100
Overall ViewNeutral
Technical Analysis ConsensusStrong Sell
Market Cap$764.22M
P/E Ratio (TTM)-7.87
Forward P/E—
EPS (Q3 FY2026)-$0.52
Revenue (Q3 FY2026)$35.51M
Dividend Yield (TTM)0.00%
Beta1.47
Volume1.38M
52-week range$8.80-$32.71
RSI 1445.53
50-Day SMA$18.47
200-Day SMA$14.82
Analyst Price Target$24.60
Next EarningsFeb 16, 2027
As of Nov 18, 2026 · Market close

BBNXBeta Bionics, Inc.

Healthcare / Medical - Devices

Low Priority

In Line With Peers

NeutralEdge 5/10
$14.33−$0.39 (−2.65%)

Latest quote

  • Momentum
    72
  • Value
    39
  • Quality
    53
  • Risk resilience
    36
  • Sentiment
    —
algovestiq.comScore data as of Nov 18, 2026

BBNX Stock Analysis Summary

Beta Bionics, Inc. (BBNX) currently has an AIQ Score of 54/100, indicating a neutral setup. Momentum is the strongest factor at 72/100. Risk resilience is the weakest current factor at 36/100. Technical, fundamental, catalyst, dividend, and risk evidence should be read together at the latest market-close snapshot.

Updated Nov 18, 2026 · Market-close data
AIQ Composite Posture: Neutral

In a neutral regime, BBNX has AIQ Score of 54/100 with Momentum base of 72/100 and fading Risk resilience at 36/100. Wait for component alignment before adding exposure.

Signal Conflict Detected

Momentum (72/100) leads while Risk resilience (36/100) lags. This cross-factor spread creates entry timing uncertainty.

Healthcare · -2.65% stock move · BBNX classified in Medical - Devices.

Current Evidence

NeutralBBNX is in a neutral AIQ regime; Momentum is the strongest visible factor at 72/100.
Core coverage reflects visible evidence only

AlgovestIQ Evidence Summary

Current consensus, supporting evidence, recent changes, and what would strengthen or weaken the view.

Is BBNX Bullish or Bearish Right Now?

BBNX currently has a neutral overall setup. Momentum is the strongest factor at 72/100, while Risk Resilience is weakest at 36/100. The current evidence suggests a mixed rather than strongly bullish or bearish setup.

Bull Case
  • - Momentum is constructive at 72/100.
  • - Analyst target implies +71.67% upside from the latest quote.
Bear Case
  • - Value is the current constraint at 39/100.
  • - Risk Resilience is weak at 36/100.
  • - Technical consensus has more sell votes than buy votes (31 vs 5).

Current Consensus

BBNX's Technical Analysis Consensus is currently Strong Sell, with 5 buy, 10 neutral, and 31 sell votes. BBNX's 14-day RSI is 45.53, which places the stock in a neutral momentum range. BBNX's beta is 1.47, indicating greater market sensitivity than the broad market.

Signal Confidence
High agreement

What Changed in BBNX?

The largest recent change in BBNX is Momentum moving down by 6.0 points over the available 7-day comparison window. Momentum remains the strongest visible factor.

AIQ Score
-1.0
Momentum
-6.0
Quality
+1.0
Risk
+0.0

What Would Change the BBNX Outlook?

The current neutral outlook could improve if AIQ reaches 65 (Bullish), momentum recovers, earnings revisions strengthen, and price confirms a stronger trend above the 50-day and 200-day moving averages. It would weaken if AIQ falls below 50 (Bearish), price loses long-term moving-average support, analyst expectations deteriorate, or risk evidence worsens.

Bullish confirmation

AIQ 65+ (Bullish), RSI above 55, price above SMA-50/SMA-200, and positive catalyst or estimate-revision evidence.

Bearish deterioration

AIQ below 50 (Bearish), RSI below 45, loss of SMA-200, negative revisions, or rising volatility and drawdown risk.

BBNX Decision Framework

Public evidence layers, setup checks, and risk context for Beta Bionics, Inc..

Beta Bionics, Inc. (BBNX) Stock Analysis

Beta Bionics, Inc. has an AIQ Score of 54/100 in a Neutral regime. Momentum is strongest at 72/100. Beta is 1.47, above market sensitivity. Review the supporting stock factors together before drawing a conclusion from any single score.

Evidence LayerPublic Evidence
Regime ContextBBNX is in a Neutral AIQ regime with score 54/100.
Signal ConflictThe primary conflict is that momentum leads at 72/100 while risk lags at 36/100.
Factor EvidenceMomentum 72/100 · Value 39/100 · Quality 53/100 · Risk 36/100
PersistenceCurrent snapshot evidence is shown; historical persistence remains in AIQ Pro.

Current Setup Checklist

Factor strengthPass

Momentum is the strongest factor at 72/100.

TimingPass

Momentum is 72/100 and RSI (14) is 45.5.

Regime fitWait

BBNX is in a Neutral regime at 54/100.

Risk controlFail

Risk factor is 36/100 with beta 1.47 and annual volatility 84.66%.

ConflictWait

Current conflict: momentum leads at 72/100 while risk lags at 36/100.

AIQ Score
54/100
Price
$14.33
Beta
1.47
RSI (14)
45.5

BBNX Research Cluster

Ticker-specific paths for valuation, technical analysis, catalysts, dividends, financials, risk, and news.

BBNX Fundamentals

BBNX valuation, profitability, growth, margins, balance-sheet strength, and free cash flow.

Revenue
$35.51M
Net income
-$24.35M
Free cash flow
-$14.56M
View full BBNX fundamental analysis

BBNX Technical Analysis

BBNX technical setup based on RSI, MACD, moving averages, AIQ Momentum, volume, trend, volatility, and pivots.

Technical Analysis Consensus
Strong Sell
RSI 14
45.53
Price vs SMA-50
-11.10%
View full BBNX technical analysis

BBNX Stock Catalysts

Track BBNX earnings, analyst ratings, price targets, estimate revisions, stock news, and upcoming events.

Next earnings
Feb 16, 2027
Analyst target
$24.60
News items
0
View BBNX earnings and stock catalysts

BBNX Dividend Analysis

BBNX dividend yield, annual dividend, payout ratio, payment history, and income reliability context.

Dividend yield
0.00%
Annual dividend
—
Payout ratio
—
View BBNX dividend history and analysis

BBNX Financial Data

BBNX revenue, earnings, income statement, balance sheet, cash flow, valuation ratios, and stock metrics.

Quarter revenue
$35.51M
EPS
-$0.52
Periods
8
View BBNX financials

BBNX Risk Analysis

BBNX volatility, beta, drawdown, Sharpe ratio, VaR, and downside resilience.

Beta
1.47
Risk score
36/100
1Y volatility
84.66%
View BBNX risk analysis

BBNX Stock News

BBNX stock news, market tone, recent headlines, and catalyst context.

News items
0
Updated
—
Sentiment
—
Read BBNX stock news

BBNX vs Medical - Devices Peers

Current peer cohort: BBNX · BFLY · BIO · BRKR · CNMD. Compare AIQ, factor scores, Sharpe ratio and 1-year volatility in one indexable view.

PeerAIQValueMomentumRiskSharpe1Y VolatilityCompare
BBNX
Current stock
54/10039/10072/10036/100-0.1684.66%Current
BFLY
Butterfly Network, Inc.
47/10029/10063/10032/1001.4121.33%BBNX vs BFLY
BIO
Bio-Rad Laboratories, Inc.
73/10080/10079/10074/1000.4736.18%BBNX vs BIO
BRKR
Bruker Corporation
64/10053/10083/10044/1000.8959.79%BBNX vs BRKR
CNMD
CONMED Corporation
71/10084/10074/10058/1000.4846.99%BBNX vs CNMD
Pairwise Compare links: BFLY · BIO · BRKR · CNMDBBNX vs BFLYBBNX vs BIOBBNX vs BRKRBBNX vs CNMDCompare cohort

Peer cohort is resolved dynamically from the AlgovestIQ universe taxonomy and Compare relationship graph. Data as of Nov 18, 2026.

About the AIQ Score

Methodology for the current stock evidence.

As of Nov 18, 2026 · Market close

The AlgovestIQ AIQ Score combines multiple dimensions of stock evidence, including momentum, valuation exposure, quality, risk resilience, sentiment context, and timing signals. It is a descriptive research score, not a guarantee of future performance or a personalized recommendation.

View AIQ methodology

Factor Diagnostics

A compact bridge from the AIQ score to the evidence tabs.

Calculator
Calculate a BBNX stock return scenario

Open the return calculator with stock context while purchase price, shares, dates and fees remain user inputs.

Calculate stock return

Also for BBNX: historical return with reinvested dividends, dollar-cost averaging (DCA) backtest and stock average calculator for several buys.

AIQ Component Profile

Compare the five component scores on one consistent 0–100 scale.

Catalyst preview

Review earnings timing, revisions, news pressure, and prior event reactions in one place.

Open catalysts
Quarterly evidence

8 recent quarterly periods are available for review.

Checked Nov 19, 2026

AIQ Pro

Explore factor drivers, conflicts, persistence, and scenario sensitivity in the advanced workspace.

Fundamentals Verdict

Current snapshot fields are separate from reported-quarter statement tables.

Current TTM P/E
-7.87
As of Nov 18, 2026
Revenue growth
30.28%
Gross margin
58.63%
Current debt / equity
0.02
Latest quarterly evidence

Latest period Sep 30, 2026.

Review fundamentals
Quarter revenue
$35.51M
Quarter net income
-$24.35M
Quarter free cash flow
-$14.56M

Market Confirmation

Technicals are summarized first, with the indicator library behind it.

Trend
Mixed
Momentum
Mixed
RSI 14
45.53
MACD
-0.55

Risk Alignment

Higher resilience is stronger; exposure metrics stay separate.

Resilience
36/100
Beta
1.47
Annual volatility
84.66%
Max drawdown
-72.30%

BBNX Stock FAQ

What is BBNX stock price today?

Beta Bionics, Inc.'s current stock price is $14.33. Use the live quote with AIQ Score, news, and risk context rather than treating price alone as a decision signal.

Is BBNX bullish or bearish right now?

BBNX's bullish or bearish read depends on the current AIQ Score, factor alignment, technical analysis consensus, valuation, risk, and catalyst evidence. A mixed setup should be treated differently from a broad confirmation across those signals.

What is BBNX's market cap?

BBNX's market cap is $764.22M based on the latest completed market-close snapshot from Nov 18, 2026. Use it with P/E ratio, revenue, and growth metrics to frame company size, valuation, and peer comparisons.

What is BBNX's current P/E ratio?

BBNX's current P/E ratio is -7.87 based on the latest completed market-close snapshot from Nov 18, 2026. Read it with revenue growth, margins, EPS, cash flow, and peer valuation rather than using P/E alone.

What is BBNX's RSI?

BBNX's 14-day RSI is 45.53 based on the latest completed market-close snapshot from Nov 18, 2026. RSI should be interpreted with MACD, moving averages, volume, volatility, and price trend.

Is BBNX above its 50-day and 200-day moving averages?

BBNX is -11.10% from its 50-day SMA and 10.82% from its 200-day SMA based on the latest completed market-close snapshot from Nov 18, 2026. Moving-average position should be read with momentum and broader AIQ evidence.

When is BBNX's next earnings date?

BBNX's next earnings date is currently listed as Feb 16, 2027. Earnings can reset revenue, EPS, price target, analyst rating, and catalyst expectations.

Does BBNX pay a dividend?

BBNX's dividend yield is 0.00% based on the latest completed market-close snapshot from Nov 18, 2026. Dividend yield should be read with payout ratio, free cash flow, growth, and balance-sheet strength.